ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.

doi:10.1002/cncy.21899

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.

Cancer cytopathology - 1 Nov 2017

Pisapia Pasquale, Lozano Maria D, Vigliar Elena, Bellevicine Claudio, Pepe Francesco, Malapelle Umberto, Troncone Giancarlo

Abstract excerpt

Cytologic sampling is the mainstay of diagnosing advanced lung cancer. Moreover, to select patients for personalized first-line or second-line treatment, epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangements are tested on cytologic preparations. Commercially available fluorescence in situ hybridization (FISH) and immunocytochemistry (ICC)...

Topics

Anaplastic Lymphoma Kinase
ErbB Receptors
Gene Rearrangement
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Lung Neoplasms
Mutation
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Receptor Protein-Tyrosine Kinases
Reproducibility of Results
Sensitivity and Specificity

Source

Open in PubMed

Identifiers

PMID: 28743163
DOI: 10.1002/cncy.21899

Genes

ALK
ROS1
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics